Literature DB >> 12091296

Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease.

M W Beresford1, R Primhak, N V Subhedar, N J Shaw.   

Abstract

In a double blind randomised controlled trial, 30 infants with chronic lung disease received fluticasone propionate or placebo for one year. There were no significant differences between treatment groups in the incidence of any day or night time symptoms or any other outcome measures.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12091296      PMCID： PMC1721440          DOI： 10.1136/fn.87.1.f62

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN： 1359-2998            Impact factor:   5.747


  8 in total

1.  Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study.

Authors:  A Kugelman; M Peniakov; S Zangen; Y Shiff; A Riskin; A Iofe; I Shoris; D Bader; S Arnon
Journal:  J Perinatol       Date:  2016-10-13       Impact factor: 2.521

Review 2.  Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.

Authors:  Wes Onland; Martin Offringa; Anton van Kaam
Journal:  Cochrane Database Syst Rev       Date:  2017-08-24

Review 3.  Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates.

Authors:  Vibhuti S Shah; Arne Ohlsson; Henry L Halliday; Michael Dunn
Journal:  Cochrane Database Syst Rev       Date:  2017-01-04

Review 4.  Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia.

Authors:  Zeyar T Htun; Elizabeth V Schulz; Riddhi K Desai; Jaime L Marasch; Christopher C McPherson; Lucy D Mastrandrea; Alan H Jobe; Rita M Ryan
Journal:  J Perinatol       Date:  2021-05-19       Impact factor: 2.521

5.  Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline.

Authors:  A Ioana Cristea; Clement L Ren; Reshma Amin; Laurie C Eldredge; Jonathan C Levin; Parevi P Majmudar; Anne E May; Rebecca S Rose; Michael C Tracy; Karen F Watters; Julian Allen; Eric D Austin; Mary E Cataletto; Joseph M Collaco; Robert J Fleck; Andrew Gelfand; Don Hayes; Marcus H Jones; Sheila S Kun; Erica W Mandell; Sharon A McGrath-Morrow; Howard B Panitch; Rizwana Popatia; Lawrence M Rhein; Alejandro Teper; Jason C Woods; Narayan Iyer; Christopher D Baker
Journal:  Am J Respir Crit Care Med       Date:  2021-12-15       Impact factor: 21.405

Review 6.  Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

Authors:  Rishika P Sakaria; Ramasubbareddy Dhanireddy
Journal:  Front Pediatr       Date:  2022-03-09       Impact factor: 3.418

Review 7.  Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis.

Authors:  Zhi-Qun Zhang; Ying Zhong; Xian-Mei Huang; Li-Zhong Du
Journal:  BMC Pulm Med       Date:  2017-12-15       Impact factor: 3.317

8.  Efficacy of glucocorticoids, vitamin A and caffeine therapies for neonatal mortality in preterm infants: a network meta-analysis.

Authors:  Ying Li; Jie Gao; Qiwei Wang; Xiaojian Ma
Journal:  Oncotarget       Date:  2017-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.